Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: Immune checkpoint inhibitors (ICIs) have become a mainstay of cancer treatment. Their immune-boosting quality has one major drawback, their proclivity to induce a broad array of immune-related adverse events (irAEs) affecting, among others, the liver and sharing some similarities with classic autoimmune liver diseases (AILD).We aimed to compare clinical, laboratory and histological features of patients with liver-related irAEs and AILD.
METHODS: We systematically compared liver irAEs with AILD, namely autoimmune hepatitis (AIH) and primary biliary cholangitis, regarding their clinical, laboratory, and histological features.
RESULTS: Twenty-seven patients with liver irAEs (ICI group) and 14 patients with AILD were identified. We observed three distinct ICI-induced histological liver injury patterns: hepatitic (52%), cholangitic (19%), and mixed (29%). When comparing the ICI and AILD groups, centrilobular injury as well as granuloma formation were more prevalent in the former (p=0.067 and 0.002, respectively). CD4+/CD8+ T cell ratios were heterogeneous between the two groups, without statistically significant difference but with a trend toward increased CD8+ T cells among hepatitic irAEs as compared with AIH. Pattern of liver function test alteration was predictive for the type of irAEs but did not correlate with histological severity.
CONCLUSIONS: Liver irAEs have broad clinical, laboratory and histological presentations. Histological features of irAEs and AILD are distinct, likely underpinning their different immunological mechanisms.
| Errataetall: |
CommentIn: J Immunother Cancer. 2023 Feb;11(2):. - PMID 36849199 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal for immunotherapy of cancer - 10(2022), 10 vom: 06. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coukos, Alexander [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents, Immunological |
|---|
| Anmerkungen: |
Date Completed 27.10.2022 Date Revised 05.01.2024 published: Print CommentIn: J Immunother Cancer. 2023 Feb;11(2):. - PMID 36849199 Citation Status MEDLINE |
|---|
| doi: |
10.1136/jitc-2022-005635 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347982662 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347982662 | ||
| 003 | DE-627 | ||
| 005 | 20240108142023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jitc-2022-005635 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1249.xml |
| 035 | |a (DE-627)NLM347982662 | ||
| 035 | |a (NLM)36283734 | ||
| 035 | |a (PII)e005635 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coukos, Alexander |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2022 | ||
| 500 | |a Date Revised 05.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Immunother Cancer. 2023 Feb;11(2):. - PMID 36849199 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND: Immune checkpoint inhibitors (ICIs) have become a mainstay of cancer treatment. Their immune-boosting quality has one major drawback, their proclivity to induce a broad array of immune-related adverse events (irAEs) affecting, among others, the liver and sharing some similarities with classic autoimmune liver diseases (AILD).We aimed to compare clinical, laboratory and histological features of patients with liver-related irAEs and AILD | ||
| 520 | |a METHODS: We systematically compared liver irAEs with AILD, namely autoimmune hepatitis (AIH) and primary biliary cholangitis, regarding their clinical, laboratory, and histological features | ||
| 520 | |a RESULTS: Twenty-seven patients with liver irAEs (ICI group) and 14 patients with AILD were identified. We observed three distinct ICI-induced histological liver injury patterns: hepatitic (52%), cholangitic (19%), and mixed (29%). When comparing the ICI and AILD groups, centrilobular injury as well as granuloma formation were more prevalent in the former (p=0.067 and 0.002, respectively). CD4+/CD8+ T cell ratios were heterogeneous between the two groups, without statistically significant difference but with a trend toward increased CD8+ T cells among hepatitic irAEs as compared with AIH. Pattern of liver function test alteration was predictive for the type of irAEs but did not correlate with histological severity | ||
| 520 | |a CONCLUSIONS: Liver irAEs have broad clinical, laboratory and histological presentations. Histological features of irAEs and AILD are distinct, likely underpinning their different immunological mechanisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CTLA-4 antigen | |
| 650 | 4 | |a autoimmunity | |
| 650 | 4 | |a cytotoxicity, immunologic | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a programmed cell death 1 receptor | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 700 | 1 | |a Vionnet, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Obeid, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Bouchaab, Hasna |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Solange |e verfasserin |4 aut | |
| 700 | 1 | |a Latifyan, Sofiya |e verfasserin |4 aut | |
| 700 | 1 | |a Wicky, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Michielin, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Chtioui, Haithem |e verfasserin |4 aut | |
| 700 | 1 | |a Moradpour, Darius |e verfasserin |4 aut | |
| 700 | 1 | |a Fasquelle, François |e verfasserin |4 aut | |
| 700 | 1 | |a Sempoux, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Fraga, Montserrat |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal for immunotherapy of cancer |d 2013 |g 10(2022), 10 vom: 06. Okt. |w (DE-627)NLM23381065X |x 2051-1426 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:10 |g day:06 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jitc-2022-005635 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 10 |b 06 |c 10 | ||